Article info
Immunogenetics
Short report
Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
- Correspondence to Dr Julie-Aurore Losman, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Julieaurore_Losman{at}dfci.harvard.edu
Citation
Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
Publication history
- Received May 14, 2018
- Revised June 12, 2018
- Accepted September 18, 2018
- First published October 4, 2018.
Online issue publication
December 13, 2018
Article Versions
- Previous version (13 December 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.